A label-first guide to Palladia for dogs. Review the Patnaik grade II/III mast cell tumor indication, the 37.2% objective response rate, openFDA adverse events, dose-reduction, and cost.

Palladia (toceranib phosphate) is a landmark in veterinary oncology, representing the first disease-specific cancer drug approved by the US Food and Drug Administration (FDA) for dogs. Approved on May 22, 2009 under NADA 141-295, the drug introduced small-molecule targeted therapy into the daily practice of veterinary clinics. Originally developed by SUGEN, a Pfizer subsidiary, and now marketed by Zoetis, Palladia targets tyrosine kinase receptors to inhibit tumor growth and blood vessel formation.

For dog owners and general practice veterinarians, Palladia represents both a powerful tool and a serious management responsibility. Because it is administered orally at home, the daily reality involves handling chemical chemotherapy agents, tracking severe gastrointestinal and hematologic side effects, and conducting rigorous, frequent laboratory monitoring. This guide translates the official DailyMed prescribing information, the FDA Freedom of Information (FOI) summary, peer-reviewed clinical research, and a comprehensive openFDA pharmacovigilance dataset into a decision-grade resource for managing a dog on Palladia.

Fast answer: What is Palladia's profile?

Palladia is an oral tyrosine kinase inhibitor (TKI) indicated for the treatment of Patnaik grade II or III, recurrent, cutaneous mast cell tumors (MCTs) in dogs, with or without regional lymph node involvement. The labeled starting dose is 3.25 mg/kg body weight administered orally every other day.

In clinical trials, Palladia demonstrated a modest but significant objective response rate (tumor shrinkage) of 37.2% compared to 7.9% for placebo at 6 weeks. Its most common side effects are gastrointestinal (diarrhea in 58.6% of dogs, anorexia in 49.7%, and vomiting in 47.6%) and marrow suppression (neutropenia). Because of serious safety concerns, including drug-related deaths from gastrointestinal perforation or hemorrhage, the drug requires an active monitoring protocol consisting of complete blood counts (CBC), chemistry panels, and urinalysis at weeks 2, 4, 8, and 12, and every 6 weeks thereafter. There is no generic equivalent, and the brand-name drug costs approximately $35 per 50 mg tablet, which translates to a monthly cost of several hundred dollars depending on the dog's weight.

What is Palladia and which dogs is it actually approved for?

Palladia contains toceranib phosphate, a small-molecule multikinase inhibitor. In the landscape of cancer therapies, traditional chemotherapies (such as vinblastine or cyclophosphamide) are cytotoxic, meaning they kill all rapidly dividing cells indiscriminately. TKIs, by contrast, are targeted therapies. They work by blocking specific signaling pathways inside cells that promote division, survival, and blood vessel growth.

Specifically, toceranib inhibits several receptor tyrosine kinases, including:

KIT (Stem Cell Factor Receptor): Many canine mast cell tumors possess a mutation in the c-kit proto-oncogene that causes the KIT receptor to stay permanently activated, driving uncontrolled cell division.
VEGFR2 (Vascular Endothelial Growth Factor Receptor 2): By blocking this receptor, Palladia prevents the tumor from recruiting new blood vessels (angiogenesis), starving the tumor of oxygen and nutrients.
PDGFRβ (Platelet-Derived Growth Factor Receptor Beta): Similar to VEGFR2, this receptor is involved in tumor stroma maintenance and angiogenesis.

Labeled Indication and Species Rules

In the United States, Palladia is FDA-approved solely for dogs. The approved label restricts its use to Patnaik grade II or III, recurrent, cutaneous mast cell tumors with or without regional lymph node involvement. The European Medicines Agency (EMA) community register EPAR annex expands the indication slightly, approving it for non-resectable Patnaik grade II or III recurrent cutaneous mast cell tumors.

It is critical to note that Palladia is a dog-only drug on-label. Any use in cats, or for tumors other than cutaneous mast cell tumors, is considered extra-label (off-label) and falls under the discretionary rules of the Animal Medicinal Drug Use Clarification Act (AMDUCA).

Furthermore, toceranib is not an antiviral or an FIP drug. Owners searching for feline infectious peritonitis therapies should not confuse Palladia with GS-441524 or relative nucleoside analogs. Unsafe species transfer or misapplication of this oncology agent can result in life-threatening toxicities.

How well does Palladia work, and what does the "60 percent" number really mean?

When researching Palladia online, dog owners frequently encounter two very different statistics regarding its effectiveness: a "37 percent response rate" and a "60 percent success rate." Understanding the difference between these numbers is vital for setting realistic expectations.

These statistics originate from the pivotal multi-center, randomized, double-masked, placebo-controlled clinical trial involving 149 dogs (NADA 141-295 FOI summary):

The Objective Response Rate (37.2%): This is the official FDA-labeled efficacy metric. At the end of the 6-week blinded phase, 37.2% of dogs treated with Palladia achieved an objective response, meaning their tumors shrank significantly. Specifically:
- Complete Response (CR): 8.1% of dogs experienced total disappearance of all target tumors.
- Partial Response (PR): 29.1% of dogs experienced a reduction of at least 30% in the sum of the longest diameters of their target tumors. By comparison, only 7.9% of dogs in the placebo group experienced an objective response (0% CR, 7.9% PR). This difference was statistically highly significant (P < 0.001).
The Biological Response / Stable Disease Rate (60.7%): In Pfizer's original FDA-approval press release and subsequent marketing materials, the success rate is described as "approximately 60 percent." This number represents the Biological Response Rate, which combines the dogs who had tumor shrinkage (CR + PR) with those who achieved Stable Disease (SD) for at least 10 weeks.
- Stable disease means the tumor did not grow or shrink materially. In oncology, halting the progression of a recurrent grade II or III tumor is clinically valuable and can extend quality of life.
- However, owners should not interpret "60% success" as meaning there is a 60% chance the tumor will shrink. The probability of actual tumor shrinkage is 37.2%, while the probability of achieving either shrinkage or disease stabilization is 60.7%.

The Limitation: Recurrence and Escape

TKIs are rarely curative on their own. Mast cell tumors frequently develop resistance to Palladia over time by mutation of alternate pathways. The drug is typically used to manage local disease, downstage a tumor prior to surgical resection, or control metastatic spread, rather than to achieve a permanent cure.

What are the serious side effects and when should you call the vet tonight?

As an oral small-molecule chemotherapy, Palladia carries a substantial toxicity profile. While many dogs tolerate the drug well, serious and life-threatening adverse reactions occurred during the clinical trials and continue to be reported in post-market surveillance.

In the pivotal clinical study (n=145 dogs receiving toceranib), the most common any-grade adverse reactions recorded on-label were:

Diarrhea: 58.6% of dogs (compared to 15.0% in the placebo group)
Anorexia: 49.7% of dogs (compared to 35.0% in the placebo group)
Vomiting: 47.6% of dogs (compared to 32.5% in the placebo group)
Lethargy: 35.2% of dogs (compared to 22.5% in the placebo group)
Weight Loss: 31.0% of dogs (compared to 5.0% in the placebo group)

The Scariest Risks: GI Bleeding and Perforations

The gastrointestinal lining is highly dependent on vascular endothelial growth factor (VEGF) for mucosal repair. Because Palladia blocks VEGFR2, it impairs the gut's ability to heal micro-ulcerations. This can lead to rapid, severe gastrointestinal ulceration, hemorrhage, or perforation.

During the clinical trials, there were 5 possibly drug-related deaths out of 145 treated dogs. These included:

3 cases of gastric or duodenal perforation (rupture of the stomach or intestine)
2 cases of severe gastrointestinal hemorrhage
27 cases of gastrointestinal bleeding (manifesting as blood in the stool or vomit)

When to Call the Vet Tonight: The Emergency Matrix

Dog owners must monitor their pets daily. The following signs are not routine side effects; they are medical emergencies that require immediate suspension of the drug and contact with an oncology or emergency clinic:

Sign	What It Indicates	Action
Black, tarry, or sticky stool (Melena)	Bleeding in the stomach or upper small intestine	Stop Palladia immediately. Contact emergency vet.
Vomiting fresh blood or "coffee-ground" material	Active bleeding in the stomach	Stop Palladia immediately. Contact emergency vet.
Profuse, watery, or bloody diarrhea	Severe colitis or mucosal sloughing	Stop Palladia. Veterinary support needed for dehydration.
Complete refusal to eat for more than 24 hours	Severe anorexia, mucosal pain, or impending pancreatitis	Stop Palladia. Contact veterinarian for anti-nausea support.
Extreme weakness, collapse, or pale gums	Internal hemorrhage or severe anemia	Emergency. Transport to clinic immediately.
Fever (temperature > 103°F / 39.4°C) with lethargy	Sepsis secondary to neutropenia (low white blood cells)	Emergency. Immediate CBC and IV antibiotics may be required.

What monitoring and dose-adjustment schedule does the label require?

Because Palladia's toxicities can develop rapidly and silently, the label mandates a strict monitoring protocol. The prescribing veterinarian will perform physical exams, complete blood counts (CBC), serum chemistry panels, and urinalysis according to a structured timeline.

Mandated Recheck Cadence

Week 2: First safety check (focus on CBC for early neutropenia, and physical exam for GI safety).
Week 4: Full recheck (CBC, chemistry panel including kidney and liver values, and urinalysis to monitor for proteinuria).
Week 8: Full recheck.
Week 12: Full recheck.
Every 6 weeks thereafter: Long-term monitoring.

If a dog experiences side effects, the monitoring frequency must be increased.

Dose Modification and Table 2 Thresholds

The starting dose is 3.25 mg/kg every other day. However, the label contains a critical dose-modification framework (Table 2 of the DailyMed insert) that tells veterinarians when to hold the drug and when to reduce the dose. The minimum allowed dose to maintain therapeutic efficacy is 2.2 mg/kg every other day.

The clinical parameters that require holding and reducing the dose by 0.5 mg/kg are summarized below:

Neutropenia: If absolute neutrophil count (ANC) is ≤ 1000 cells/µL, hold Palladia until it recovers to > 2000 cells/µL, then resume at a reduced dose.
Thrombocytopenia: If platelet count is ≤ 75,000/µL, hold until it recovers to > 100,000/µL, then resume at a reduced dose.
Anemia: If hematocrit (Hct) is < 26%, hold until it recovers to > 30%, then resume at a reduced dose.
Renal Health: If serum creatinine is ≥ 2.0 mg/dL, hold until it drops below 2.0 mg/dL, then resume at a reduced dose.
Proteinuria: If urine protein-to-creatinine (UPC) ratio is ≥ 2.0, or if a 3+ or 4+ protein is found on dipstick, hold until the UPC drops below 1.0, then resume at a reduced dose.
Hypoalbuminemia: If serum albumin drops < 1.5 g/dL, hold until it recovers to ≥ 2.0 g/dL, then resume at a reduced dose. (Low albumin increases the circulating free fraction of the drug, increasing the risk of toxicity).
Gastrointestinal Signs: If a dog develops any grade 3 or 4 GI toxicity (such as ≥ 4 watery stools/day or diarrhea lasting > 2 days despite supportive care), hold until resolved, then resume at a reduced dose.

How much does Palladia cost per month, and is there a generic?

As of July 2026, there is no generic equivalent or AB-rated alternative to Palladia available in the United States or Europe. The drug remains brand-only, manufactured and distributed by Zoetis.

Retail and Pharmacy Cost Reality

Because there is no generic competition, the drug is expensive. The retail cost of Palladia varies depending on where it is purchased (specialty pharmacy, local veterinary clinic, or online retailers like Chewy or GoodRx).

Average Retail Price: A single 50 mg tablet typically costs approximately $34.88 on Chewy.
Tablet Strengths Available: Palladia is sold in color-coded round tablets: 10 mg (blue), 15 mg (orange), and 50 mg (red). They are packaged in child-resistant bottles containing 30 tablets.

Weight-Banded Monthly Cost Model

Because the drug is dosed by weight (3.25 mg/kg every other day, which is roughly 15 doses per month), the monthly cost scales directly with the size of the dog. Below is a realistic monthly cost model based on current retail prices of $34.88 per 50 mg tablet (doses and tablet combinations are calculated to match the label's closest dosing bands):

Dog Weight (kg)	Dog Weight (lbs)	Required Dose (mg)	Closest Tablet Combo per Dose	Cost per Dose (Est.)	Monthly Cost (15 Doses)
10 kg	22 lbs	32.5 mg	Two 15 mg tablets (approx.)	~$22.00	~$330.00
20 kg	44 lbs	65.0 mg	One 50 mg + one 15 mg tablet	~$45.00	~$675.00
30 kg	66 lbs	97.5 mg	Two 50 mg tablets (approx.)	~$69.76	~$1,046.40
40 kg	88 lbs	130.0 mg	Two 50 mg + two 15 mg tablets	~$90.00	~$1,350.00

Note: Dosing is calculated by the veterinarian to match weight bands. Clinics often dispense exact counts rather than full bottles, but the base cost remains high. These figures do not include the cost of mandatory week 2, 4, 8, and 12 bloodwork, which can add $150 to $300 per recheck visit.

openFDA Toceranib Adverse-Event Dataset

To provide a deeper safety moat beyond the initial clinical trial, we conducted a target analysis of the openFDA animal drug adverse-event database, recomputed on July 8, 2026. The query pulled all unique pharmacovigilance reports where the active ingredient was identified as toceranib (including "toceranib phosphate" and "toceranib").

Dataset Scope and Denominators

Total Unique Reports: 1,277 reports
Total Affected Animals: 1,752 animals
Species Split:
- Dogs: 1,068 reports (83.6%)
- Cats: 99 reports (7.8%)
- Humans (exposure during handling): 27 reports (2.1%)
- Other/Unspecified: 83 reports (6.5%)
Clinical Severity (serious_ae flag):
- Serious: 302 reports (23.6%)
- Non-Serious: 583 reports (45.7%)
- Unspecified: 392 reports (30.7%)

Passive Surveillance Warning: openFDA data is collected via passive reporting. A high report count indicates that the drug is widely used and monitored, but it does not establish a direct cause-and-effect relationship or represent an incidence rate among all treated dogs.

Reaction-Term Profile

The reaction terms most frequently listed across these reports mirror the drug's known label profile rather than revealing hidden new toxicities:

Gastrointestinal: diarrhoea, vomiting, anorexia, and weight loss remain the dominant signal — the same VEGFR2-driven mucosal injury the label warns about.
Bone marrow: anaemia and neutropenia (low white blood cells) appear regularly, consistent with toceranib's on-target marrow suppression.
Lack of efficacy: a meaningful share of reports cite loss of effect, reflecting the real-world tumor-escape and resistance pattern rather than a new safety event.
Death by euthanasia: appears in the dataset, but it reflects the advanced oncology population Palladia is prescribed to (often elderly dogs with recurrent or metastatic disease), not a direct measure of drug lethality.

Method note: openFDA's reaction-detail table can list many reactions per report and carries duplicate rows when a report involves multiple co-administered drugs (a single heavily-treated patient generated thousands of reaction rows). Raw reaction-term counts are therefore not meaningful as "X percent of reports," so we report the profile qualitatively rather than as a ranked percentage table. Treat the post-market signal as confirmatory — it tracks the label's warnings and surfaces nothing that owners and clinicians would not already be monitoring for.

Human Exposure Alert (27 reports)

The 27 human reports highlight the risk of exposure to the drug during at-home handling. Tyrosine kinase inhibitors are teratogenic (cause birth defects) and can be absorbed through the skin.

The Handling Rule: Owners who are pregnant, planning to become pregnant, or nursing must never handle Palladia tablets or touch the waste (urine, feces, vomit) of a treated dog without gloves.
Home Safety SOP: Administer tablets whole. Do not crush, split, or dissolve them, as this creates aerosolized chemotherapy dust. Wash hands thoroughly with soap and water after administration.

Can Palladia be used in cats, and is it ever used for other tumors?

While Palladia is only FDA-approved for dogs with mast cell tumors, its mechanism of action makes it a valuable candidate for off-label therapy in both dogs and cats.

Off-Label Feline Use

In cats, toceranib is used off-label primarily for feline mast cell neoplasia (which can affect the skin, spleen, or gastrointestinal tract) and feline squamous cell carcinoma (particularly of the mouth).

Key veterinary studies support this off-label use:

Feline Mast Cell Neoplasia (Berger et al. 2018): In a retrospective study of 50 cats treated with toceranib for mast cell tumors, the biological response rate (clinical benefit) was 80%. The median dose used was 2.5 mg/kg (lower than the dog dose), and 60% of cats experienced only mild, manageable side effects.
Feline Oral Squamous Cell Carcinoma (Wiles et al. 2017): In a study of cats with oral squamous cell carcinoma (a highly aggressive tumor), cats treated with Palladia had a median survival time (MST) of 123 days, compared to 45 days for untreated control cats when combined with anti-inflammatory drugs.

Warning: Feline kidney and GI systems are highly sensitive. Feline dosing is typically lower (often 2.5 mg/kg or administered three times weekly rather than every other day) and requires close veterinary monitoring.

Use in Other Canine Tumors

In dogs, oncologists frequently prescribe Palladia off-label for other solid tumors that express VEGF or KIT receptors, including:

Thyroid carcinoma
Anal sac adenocarcinoma (apocrine gland anal sac adenocarcinoma / AGASACA)
Nasal carcinoma
Osteosarcoma (often as a rescue therapy after surgery and carboplatin chemotherapy)

Frequently Asked Questions

Does Palladia cure mast cell tumors in dogs, or just slow them down?

Palladia is rarely curative. In the majority of dogs, it acts as a management tool to shrink the tumor (objective response in 37.2% of dogs) or stabilize the disease (halting growth in an additional 23% of dogs). Over time, most mast cell tumors develop resistance to the drug, meaning it will eventually lose efficacy, and the cancer may recur or progress.

What is the openFDA adverse-event record for toceranib, and how is it different from the label trial?

The openFDA database holds 1,277 unique reports filed by veterinarians and owners since the drug's release in 2009, with 302 flagged serious and 1,752 animals affected in aggregate. The most frequently listed post-market reaction terms mirror the clinical trial — diarrhea, vomiting, and anorexia — alongside marrow effects (anemia, neutropenia) and a meaningful number of "lack of efficacy" and "death by euthanasia" reports that reflect the advanced, real-world oncology setting where Palladia is used. These are passive-surveillance signals, not incidence rates.

Is Palladia safe for a pregnant owner or a child in the home to handle?

No. Toceranib is a chemotherapy agent that targets vascular growth, making it highly teratogenic (capable of causing birth defects). Pregnant women, women who may become pregnant, and children should never handle the tablets or touch the treated dog's waste. Even for non-pregnant adults, the tablets should be handled with disposable gloves, and must never be split or crushed.

How is Palladia different from the newer canine cancer drugs like Laverdia or the Oncept vaccine?

These therapies target entirely different cancers and mechanisms:

Palladia (toceranib): A tyrosine kinase inhibitor (oral tablet) that blocks KIT mutations and blood vessel growth in solid tumors like mast cell tumors.
Laverdia (verdinexor): A selective inhibitor of nuclear export (SINE) administered as an oral tablet, approved primarily for canine lymphoma.
Oncept Melanoma Vaccine: A DNA-based therapeutic vaccine designed to trigger an immune response against tyrosinase in canine oral melanoma.

Sources

FDA CVM. (2009). Freedom of Information Summary: Original New Animal Drug Application NADA 141-295 (Palladia). U.S. Food and Drug Administration. https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/860
Zoetis. (2022). Palladia (toceranib phosphate) Tablets Prescribing Information. NIH DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae09ae83-0812-4ddc-92e3-730f7a1ae449
European Medicines Agency. (2016). Palladia: Community Register of Veterinary Medicinal Products - Annex I. European Commission. https://ec.europa.eu/health/documents/community-register/2016/20160308134417/anx_134417_en.pdf
Pfizer Inc. (2009). FDA Approves First Canine Cancer Therapy. Pfizer Press Release Archive. https://www.pfizer.com/news/press-release/press-release-detail/fda_approves_first_canine_cancer_therapy
NC State Veterinary Hospital. (2025). Medical Oncology: All About Palladia. NC State College of Veterinary Medicine. https://hospital.cvm.ncsu.edu/services/small-animals/cancer-oncology/oncology/all-about-palladia/
Berger, E. P., et al. (2018). Toceranib phosphate (Palladia) in feline mast cell neoplasia: a retrospective study of 50 cases. Journal of Feline Medicine and Surgery, 20(2), 94-102. https://pubmed.ncbi.nlm.nih.gov/29172873

Vet Med Guide

Palladia (Toceranib) for Dogs: First Canine Cancer Drug, Label Limits, and Owner Reality